Skip to main content

Orion Corporation: Change in Orion Group Executive Management Board as of 1 May 2020

Written by Customer Service on . Posted in Public Companies.

ORION CORPORATION        STOCK EXCHANGE RELEASE       28 April 2020 at 12.15  EEST             
         Orion Corporation: Change in Orion Group Executive Management Board as of 1 May 2020Mr. Markku Huhta-Koivisto, Senior Vice President, Growth Projects and member of the Executive Management Board of the Orion Group will retire in July 2020. He will step aside from his current positions and leave the Executive Management Board of the Orion Group as of 1 May 2020.Markku Huhta-Koivisto’s responsibilities will be transferred to other members of the Executive Management Board and other management, and no successor to the Executive Management Board for Mr. Huhta-Koivisto will be appointed.Timo Lappalainen, President and CEO, says:”Markku Huhta-Koivisto has made a long and distinguished career in Orion. Versatile experience from different positions has given Markku an extremely robust and wide expertise in pharmaceutical business. This has been very valuable for Orion in the development of the company in various stages. It is my pleasure to thank Markku for his excellent contribution when leading various parts of Orion during many decades.” Markku Huhta-Koivisto says:”With wistful feelings I will retire from Orion after 37.5 years of service. I am grateful for having had the opportunity to work in many leadership positions in different parts of Orion with very committed and talented professionals. While leaving Orion, I look to the company’s future with a great deal of confidence.”
Orion Corporation                                                                                                                                   
Contact person:
Timo Lappalainen, President and CEO, Orion Corporation
tel. +358 10 426 3692, +358 50 966 3692
timo.lappalainen@orion.fiPublisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIROrion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion’s pharmaceutical R&D are central nervous system (CNS) disorders, oncology, Finnish heritage rare diseases and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs. Orion’s net sales in 2019 amounted to EUR 1,051 million and the company had about 3,300 employees at the end of the year. Orion’s A and B shares are listed on Nasdaq Helsinki.

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.